Drug major Cipla today said its subsidiary has secured rights from Hyderabad-based MSN Laboratories to market and distribute colon cancer treatment drug Capecitabine in the US market.
Cipla USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.
The company`s product is generic equivalent of Genentech`s Xeloda.
Capecitabine tablets are indicated in patients with colon cancer and for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
As per IQVIA (IMS Health) dat, Xeloda and its generic equivalents had sales of around USD 178 million in the US for 12-month period ending June 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.